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SUMMARY
Early B cell development is regulated by stage-spe-
cific transcription factors. PU.1, an ETS-family tran-
scription factor, is essential for coordination of early
B cell maturation and immunoglobulin gene (Ig) rear-
rangement. Here we show that RAG DNA double-
strand breaks (DSBs) generated during Ig light chain
gene (Igl) rearrangement in pre-B cells induce global
changes in PU.1 chromatin binding. RAG DSBs acti-
vate a SPIC/BCLAF1 transcription factor complex
that displaces PU.1 throughout the genome and reg-
ulates broad transcriptional changes. SPIC recruits
BCLAF1 to gene-regulatory elements that control
expression of key B cell developmental genes. The
SPIC/BCLAF1 complex suppresses expression of
the SYK tyrosine kinase and enforces the transition
from large to small pre-B cells. These studies reveal
that RAG DSBs direct genome-wide changes in
ETS transcription factor activity to promote early B
cell development.
INTRODUCTION
B cell development requires the sequential assembly and
expression of genes encoding the immunoglobin heavy (Igh)
and immunoglobulin light (Igl) chains to generate a mature B
cell receptor (BCR) (Rajewsky, 1996). Ig genes are assembled
through the process of V(D)J recombination, which joins distant
variable (V), joining (J), and diversity (D) segments (Fugmann
et al., 2000). The DNA double-strand breaks (DSBs) necessary
for V(D)J recombination are generated by the RAG endonu-
clease, which is composed of the RAG1 and RAG2 proteins
(Fugmann et al., 2000). RAG-mediated DNA breaks are gener-
ated in the G1 phase of the cell cycle and activate the DNA dam-
age response (DDR) kinase ATM, which facilitates repair of the
broken DNA ends through nonhomologous end joining (Helmink
and Sleckman, 2012). In response to RAG DSBs, ATM also acti-
vates a broad transcriptional program that regulates genes
involved in diverse B cell functions, including migration, cell-cy-
cle arrest, survival, and differentiation (Bednarski et al., 2012,
2016; Bredemeyer et al., 2008; Helmink and Sleckman, 2012;
Steinel et al., 2013). This genetic program is mediated by ATM-
dependent activation of several transcription factors, including
NF-kB1, NF-kB2, and SPIC (Bednarski et al., 2012, 2016; Brede-
meyer et al., 2008).
The Igh gene is assembled first in pro-B cells and productive
rearrangement results in its surface expression with surrogate
light chains (l5 and VpreB) to generate the pre-BCR, which sig-
nals transition to the large pre-B cell stage (Clark et al., 2014;
Herzog et al., 2009; Rajewsky, 1996). Pre-BCR oligomerization
signals through the SYK tyrosine kinase to promote proliferation
and clonal expansion of large pre-B cells (Clark et al., 2014; Her-
zog et al., 2009). Activation of SYK also triggers Iglk (Igk) gene
recombination (Clark et al., 2014). RAG expression is sup-
pressed in proliferating cells, and as such, Igk gene assembly re-
quires induction of cell-cycle arrest and transition to the small,
non-proliferating pre-B cell stage (Clark et al., 2014; Desiderio
et al., 1996; Johnson et al., 2008; Ochiai et al., 2012). RAG
DSBs activate ATM-dependent DDR signaling pathways that
enforce cell-cycle arrest and promote survival to prevent prolifer-
ation of cells with unrepaired DSBs and permit time for proper
assembly of Igk genes (Bednarski et al., 2012, 2016; DeMicco
et al., 2016).
B cell development and assembly of Ig genes are carefully
orchestrated by developmental stage-specific transcription fac-
tors, including E2A, EBF, Pax5, PU.1 and SPIB (Pang et al.,
2014). The ETS-family transcription factor PU.1 is required for
B cell lineage commitment and is constitutively expressed
throughout B cell development (Polli et al., 2005; Schweitzer
and DeKoter, 2004; Scott et al., 1994, 1997). PU.1 has critical
functions during B cell maturation. In pre-B cells, PU.1 regulates
expression of a diverse genetic program, including genes
involved in B cell proliferation, differentiation, and Ig gene rear-
rangement (Batista et al., 2017; Heinz et al., 2010; Solomon
et al., 2015). Expression of SYK and germline transcription of
Igk, which are required for pre-BCR signaling and initiating V(D)
J recombination, respectively, depend on PU.1 activity (Batista
et al., 2017; Herzog et al., 2009; Schwarzenbach et al., 1995;
Schweitzer and DeKoter, 2004). Interestingly, loss of PU.1 in B
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Figure 1. RAG DSB Signals Induce Genome-wide Changes in PU.1 Binding
(A) qPCR analysis of Igk genomic DNA fromRag1/:Bcl2 (red) andArt/:Bcl2 (blue) abl pre-B cells treatedwith imatinib for 48 h. Schematic shows germline (GL)
Igk locus and unrepaired Jk1 coding end with location of PCR primers. PCR is normalized to Rag1/:Bcl2 abl pre-B cells, which do not generate RAG DSBs and
have only intact germline Igk DNA. Data are representative of three independent experiments.
(legend continued on next page)
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cell progenitors results in only amild defect in B cell development
because of compensatory function of another ETS-family tran-
scription factor, SPIB (Polli et al., 2005; Sokalski et al., 2011;
Ye et al., 2005). PU.1 and SPIB associate with nearly identical re-
gions of the genome in B cells and regulate transcription of a
similar cohort of genes (Solomon et al., 2015). Combined loss
of PU.1 and SPIB impairs B cell maturation in the bone marrow
and predisposes to the development of B cell leukemia (Sokalski
et al., 2011).
We previously demonstrated that SPIC, an ETS-family tran-
scriptional repressor with homology to PU.1 and SPIB, also func-
tions in pre-B cells (Bednarski et al., 2016; Bemark et al., 1999;
Hashimoto et al., 1999). Unlike PU.1 and SPIB, SPIC is not
constitutively expressed in early B cells but, rather, is induced
by signals from RAG DSBs (Bednarski et al., 2016). SPIC oper-
ates primarily as a transcriptional repressor and counters the
activating functions of PU.1 and SPIB (Li et al., 2015; Zhu
et al., 2008). In pre-B cells, SPIC suppresses expression of Syk
and Blnk, which inhibits pre-BCR signaling and enforces cell-cy-
cle arrest in pre-B cells with RAG DSBs (Bednarski et al., 2016).
SPIC also inhibits transcription of Igk to prevent generation of
additional RAG DSBs (Bednarski et al., 2016). Binding of SPIC
to gene-regulatory elements for Syk, Blnk, and Igk is associated
with loss of PU.1 at these genomic regions. Thus, expression of
SPIC antagonizes PU.1 as these identified genes to suppress
transcription and coordinate pre-B cell development.
Whether SPIC has broader functions in gene regulation and its
mechanism of action in B cells have not been defined. SPIC may
oppose PU.1 at limited gene targets or, alternatively, maymodu-
late PU.1 activity throughout the genome. In this regard, attenu-
ation of PU.1 activity by SPIC could suppress pre-B cell genetic
programs to promote continued B cell maturation. SPIC may
function simply by displacing PU.1 through competition for
DNA binding sites or may complex with other transcriptional reg-
ulators to repress transcription. We show here that, in response
to RAG DSBs, SPIC binds throughout the genome of pre-B cells
and elicits global changes in PU.1 chromatin association. SPIC
associates with the transcriptional repressor BCLAF1 (Bcl2-
associated factor 1) to regulate a distinct subset of RAG DSB-
dependent gene expression changes and to enforce transition
from large to small pre-B cells. These experiments provide
insight into the regulation of ETS transcription factors in early B
cells and the impact of DDR signaling on B cell development.
RESULTS
RAGDSBSignals InduceGenome-Wide Changes in PU.1
Binding
To determine the effects of DNA damage signaling on PU.1 ac-
tivity in early B cells, we used Abelson-kinase transformed
pre-B cells (abl pre-B cells) deficient in RAG1 or the Artemis
endonuclease that express the Bcl2 transgene (Rag1/:Bcl2
and Art/:Bcl2, respectively) (Bredemeyer et al., 2008). Expres-
sion of the Abl kinase promotes pre-B cell proliferation and sup-
presses expression of Rag1 and Rag2. Treatment with the Abl
kinase inhibitor imatinib triggers cell-cycle arrest, induction of
RAG expression, and recombination of Igk (Bredemeyer et al.,
2008). The Bcl2 transgene supports survival of imatinib-treated
cells. Following treatment with imatinib, Rag1/:Bcl2 abl
pre-B cells do not generate RAG DSBs. In contrast, Art/:Bcl2
abl pre-B cells generate RAG DSBs at Igk, but these DSBs are
not repaired as Artemis is required to open hairpin-sealed coding
DNA ends (Figure 1A) (Bredemeyer et al., 2008; Helmink and
Sleckman, 2012). The RAG DSBs in Art/:Bcl2 abl pre-B cells
activate ATM-dependent DDRs (Bednarski et al., 2012, 2016;
Bredemeyer et al., 2008).
Chromatin immunoprecipitation followed by next-generation
DNA sequencing (ChIP-seq) reveals global changes in PU.1
binding in pre-B cells with RAG DSBs (Art/:Bcl2) compared
with pre-B cells without RAG DSBs (Rag1/:Bcl2), despite no
differences in PU.1 expression (Figures 1B, 1C, and S1A). Induc-
tion of RAGDSBs results in gain of few new binding sites but loss
of approximately 20% of the PU.1 binding sites identified in
Rag1/:Bcl2 abl pre-B cells (Figure 1B). Gene Ontology anal-
ysis demonstrates that genes within 12 kb of lost PU.1 binding
sites are involved in immune cell activation and differentiation
(Figure S1B). In contrast, PU.1 binding sites that are conserved
between Rag1/:Bcl2 and Art/:Bcl2 abl pre-B cells are prox-
imal to genes involved in cell homeostasis and maintenance
(i.e., signaling, nuclear transport, apoptosis). Novel RAG DSB-
induced PU.1 binding occurred near genes involved in cell adhe-
sion and developmental processes. Induction of RAG DSBs did
not alter PU.1 binding across genomic regulatory elements as
equal binding to promoters, genes, or intergenic regions (i.e., en-
hancers) is observed in both Rag1/:Bcl2 and Art/:Bcl2 abl
pre-B cells (Figure S1C). Thus, in response to RAG DSBs,
pre-B cells have a genome-wide reduction in PU.1 chromatin
binding, which is expected to result in changes in gene expres-
sion that affect important cellular functions.
Expression of SPIC Alters PU.1 Binding in Pre-B Cells
RAG DSBs trigger ATM-dependent induction of SPIC (Figure 2A).
Expressionof SPIC, in turn, results in loss of PU.1 binding at genes
required for pre-BCR signaling (Bednarski et al., 2016). To deter-
mine if expression of SPIC is responsible for the global changes
in PU.1 binding observed in response to RAG DSBs, we stably
transduced Rag1/:Bcl2 abl pre-B cells with a lentiviral
vector encoding a tetracycline-inducible FLAG-HA-tagged
SPIC (Rag1/:Bcl2:Spictet). Treatment with doxycycline induced
equivalent SPIC mRNA expression as triggered by RAG DSBs
(Figures 2A and 2B). We performed ChIP-seq for PU.1 in
Rag1/:Bcl2:Spictet abl pre-B cells treated with imatinib alone
or in combination with doxycycline to induce expression of SPIC
(Figure 2B). Expression of SPIC does not alter PU.1 expression
(B) Dot plot and heatmap of fold changes and signal intensity for PU.1 peaks identified by ChIP-seq in Rag1/:Bcl2 and Art/:Bcl2 abl pre-B cells treated with
imatinib for 48 h. Data are from common peaks identified in two replicates for each cell.
(C) Representative tracks at indicated regions for PU.1 ChIP-seq from (B). ChIP-qPCR validation for PU.1 binding at each locus is also shown. Data are mean and
SE for three independent experiments. **p% 0.01 and ****p% 0.0001; ns, not significant.
See also Figure S1.
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but results in significant changes in PU.1 chromatin binding
(Figures 2C and 2D). Moreover, expression of SPIC results in
changes in PU.1 binding that are similar to changes induced by
RAG DSBs (compare Figures 1B and 2D). These findings demon-
strate that changes in PU.1 binding in response to RAGDSBs are,
in large part, due to RAG DSB-mediated induction of SPIC.
Figure 2. Expression of SPIC Alters PU.1 Binding
(A) SpicmRNA expression inRag1/:Bcl2 and Art/:Bcl2 abl pre-B cells treated with imatinib for 48 h. Art/:Bcl2 abl pre-B cells were also treated with vehicle
() or 15 mM ATM inhibitor KU55933 (+ iATM). Data are relative to Rag1/:Bcl2 and are mean and SE for three independent experiments.
(B) SpicmRNA expression in Rag1/:Bcl2:Spictet abl pre-B cells treated with imatinib alone () or with imatinib and 2 mM doxycycline (Dox; +) for 48 h. Data are
relative to Rag1/:Bcl2:Spictet without doxycycline and are mean and SE for three independent experiments.
(C) Western blot shows PU.1 and SPIC (determined by anti-FLAG antibody) in Rag1/:Bcl2:Spictet abl pre-B cells treated as in (B). Data are representative of
three independent experiments.
(D) Dot plot and heatmap of fold changes and signal intensity for PU.1 peaks identified by ChIP-seq in Rag1/:Bcl2:Spictet abl pre-B cells treated with imatinib
alone ( Dox, no SPIC) or with imatinib and 2 mM doxycycline (+ Dox, + SPIC) for 48 h as in (B). Data are from common peaks identified in two replicates for each
cell line.
*p% 0.05.
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SPIC and PU.1 Bind to Identical Genomic Regions
SPIC and PU.1 have homologous DNA binding domains and
have been previously shown in vitro to bind to the same DNA
sequence (Bemark et al., 1999; Hashimoto et al., 1999). Current
commercial antibodies against endogenous SPIC do not work
for ChIP. Thus, to determine if SPIC and PU.1 binding to
chromatin is similarly distributed throughout the genome, we
performed ChIP-seq with anti-HA antibodies to precipitate
FLAG-HA-SPIC in Rag1/:Bcl2:Spictet abl pre-B cells treated
with doxycycline (to induce SPIC). Results were compared
with findings from ChIP-seq for PU.1 in Rag1/:Bcl2 abl pre-B
cells without SPIC expression. Peaks withR1 bp of overlap be-
tween the two ChIP-seq datasets were considered as enriched
for binding to both transcription factors. We find that SPIC and
PU.1 bind to similar locations throughout the genome (Figure
3A). Additionally, PU.1 binding is lost at sites where SPIC is
bound (Figures 3B, 3C, and S2).
The ChIP peaks for SPIC and PU.1 in regions where both tran-
scription factors bind (common peaks in Figure 3A) have signif-
icant nucleotide overlap (Figures 3D). Indeed, the majority of
these shared binding sites overlap by >70%, and the greatest
number of ChIP peaks have >90% overlap. Furthermore, SPIC
and PU.1 bind to similar regions throughout the genome (Fig-
ure 3E). Collectively, these findings demonstrate that SPIC and
PU.1 bind to similar regulatory elements in pre-B cells and that
SPIC binding results in displacement of PU.1 from these regions.
SPIC Recruits BCLAF1 to Chromatin
PU.1 forms heterodimeric complexes with IRF4 or IRF8 to regu-
late transcription initiation (Brass et al., 1996; Heinz et al., 2010).
SPIC does not complex with IRF4 or IRF8 but binds to similar
DNA sequences as PU.1 (Carlsson et al., 2003). These findings
raise the question of whether SPIC complexes with distinct
protein partners to regulate gene expression. To identify SPIC in-
teracting partners, we generated Art/:Bcl2 abl pre-B cells ex-
pressing either a tetracycline-inducible FLAG-HA-tagged SPIC
(Art/:Bcl2:Spictet) or a tetracycline-inducible FLAG-HA-tagged
PU.1 (Art/:Bcl2:Pu1tet). Cells were treated with imatinib to
induce RAG DSBs and with doxycycline to induce comparable
expression of the FLAG-tagged transcription factors (Figure S3).
SPIC and PU.1 were immunoprecipitated using anti-FLAG anti-
bodies, and associated proteins were identified by tandem
mass spectrometry. Unique peptides were compared with iden-
tify proteins enriched for binding to SPIC (Figure 4A; Table S1).
We focused on nuclear proteins with functions in transcriptional
regulation. One of these proteins that enriched for binding to
SPIC and not PU.1 is BCLAF1 (Figures 4A and 4B). BCLAF1
was originally identified as a transcriptional repressor but has
also been shown to promote gene expression in response to
DNA damage (Kasof et al., 1999; Liu et al., 2007; Shao et al.,
2016). Bclaf1-deficient mice have reduced T cells and increased
splenic B cell numbers, suggesting that BCLAF1 may function in
immune development (McPherson et al., 2009).
Reciprocal co-immunoprecipitation experiments demonstrate
that BCLAF1 selectively associates with SPIC and not PU.1
in Art/:Bcl2 abl pre-B cells (Figures 4B and 4C). In contrast,
IRF4 and IRF8 associate with PU.1 but do not complex
with SPIC (Figure 4B). To determine if BCLAF1 is recruited to
SPIC-bound chromatin in pre-B cells, we compared BCLAF1
ChIP-seq with SPIC ChIP-seq. A significant portion (>80%) of
BCLAF1 and SPIC peaks overlap indicating that the two proteins
associate with similar chromatin regions (Figure 4D). Consistent
with ChIP-seq results, BCLAF1 binding to the Syk promoter is
increased in cells expressing SPIC (Figure 4E). Additionally,
ChIP-re-ChIP experiments show that BCLAF1 only associates
with the SPIC-bound Syk promoter and not with the PU.1-bound
promoter (Figure 4F). Finally, BCLAF1 binding to the Syk pro-
moter is increased in pre-B cells with RAG DSBs (Art/:Bcl2),
which express SPIC (Figures 4G and 2A). BCLAF1 ChIP peaks
contain the conserved ETS DNA binding sequence (GGAA, p <
13 e33) suggesting that it may not directly bind DNA but rather
is recruited to chromatin by SPIC in response to RAG DSBs in
pre-B cells.
SPIC and BCLAF1 Regulate Gene Expression in Pre-B
Cells
We previously showed that in response to RAG DSBs, SPIC re-
presses expression of key genes required for pre-BCR signaling
(Bednarski et al., 2016). Given our current findings that SPIC and
its partner BCLAF1 bind throughout the genome, we hypothe-
sized that this complex regulates a broad genetic program in
pre-B cells. To identify the genes regulated by SPIC, we
compared transcriptional changes in Rag1/:Bcl2:Spictet abl
pre-B cells with and without expression of SPIC. Expression of
866 genes was changed R2-fold (adjusted p < 0.05) following
expression of SPIC (Figures 5A and S4A; Table S2). Knockdown
of BCLAF1 in SPIC-expressing Rag1/:Bcl2:Spictet abl pre-B
cells changes expression of 55% of SPIC-regulated genes
(R2-fold change, adjusted p < 0.05) (Figures 5B, 5C, and S4A;
Table S2). Notably, genes repressed by SPIC were rescued
following knockdown of BCLAF1 (Figures 5C and S4A). Gene
Ontology analysis revealed that SPIC- and BCLAF1-dependent
genes are enriched for immune processes in B cells (Figure S4B).
Importantly, loss of BCLAF1 does not alter SPIC binding to the
Syk promoter, suggesting that recruitment of BCLAF1 is needed
for SPIC-mediated transcriptional changes but not for SPIC
binding to chromatin (Figure 5D).
We then determined the contribution of SPIC/BCLAF to the
genetic program regulated by RAG DSBs in pre-B cells. Gene
profiling revealed that BCLAF1 regulates a significant portion
of RAG DSB-mediated genes (540 of 717 genes, R2-fold
change, adjusted p < 0.05; Figure 5E; Table S3). Comparison
of RAG DSB-dependent (Art/:Bcl2 versus Rag1/:Bcl2; Fig-
ure 5E), SPIC-dependent (Rag1/:Bcl2:Spictet expressing
SPIC versus Rag1/:Bcl2; Figure 5A), and BCLAF1-dependent
(Art/:Bcl2 expressing shBCLAF1 versus Art/:Bcl2; Fig-
ure 5E) gene expression changes identified 141 genes whose
expression is modulated by all three variables (Figures 5F, 5G,
and S5A; Table S4). Approximately 25% of these genes have
concordant changes in expression (repressed by RAG DSBs,
repressed by SPIC, and rescued by loss of BCLAF1; Figure S5A).
Pathway analyses are enriched for diverse B cell functions,
including proliferation, cell adhesion, and cell death (Figure S5B).
These findings demonstrate that the SPIC/BCLAF1 complex
regulates a distinct genetic program in pre-B cells with RAG
DSBs.
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Figure 3. SPIC and PU.1 Bind to Identical Genomic Regions
(A) Dot plot and heatmap of fold changes and signal intensity for PU.1 and SPIC (by anti-HA ChIP) peaks identified by ChIP-seq in Rag1/:Bcl2:Spictet abl pre-B
cells treated with imatinib for 48 h in the absence (for PU.1 ChIP) or presence (for SPIC ChIP) of 2 mMdoxycycline (Dox). Data are from common peaks identified in
two replicates of each cell line.
(B) Representative ChIP-seq binding of PU.1 and SPIC at indicated regions. PU.1 ChIP-seq was performed in Rag1/:Bcl2:Spictet abl pre-B cells treated with
imatinib alone (Dox, no SPIC) or with imatinib and doxycycline to induce expression of SPIC (+ Dox, + SPIC) for 48 h. ChIP-seq for SPICwas performed as in A in
Rag1/:Bcl2:Spictet abl pre-B cells treated with imatinib and doxycycline for 48 h.
(legend continued on next page)
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BCLAF1 Regulates Pre-BCR Signaling in Primary Pre-B
Cells
To determine if BCLAF1 is required for regulation of SPIC
function in primary pre-B cells, we expanded pre-B cells
from Rag1/:mIgh:Bcl2 and Art/:mIgh:Bcl2 mice in the pres-
ence of interleukin-7 (IL-7) (Bednarski et al., 2012, 2016). The
mIgh transgene permits expression of a pre-BCR, which pro-
motes transition to the pre-B cell developmental stage (Bed-
narski et al., 2012, 2016). IL-7 promotes proliferation and
expansion of large pre-B cells. Withdrawal of IL-7 induces
cell-cycle arrest, transition to small pre-B cells, expression
of RAG, and induction of RAG DSBs at Igk (Bednarski et al.,
2012, 2016; Johnson et al., 2008; Ochiai et al., 2012; Rolink
et al., 1991; Steinel et al., 2013). Consistent with our previous
findings, withdrawal of IL-7 results in induction of SPIC and
suppression of Syk transcripts in pre-B cells with RAG DSBs
Figure 4. SPIC Recruits BCLAF1 to
Chromatin
(A) FLAG-HA-SPIC and FLAG-HA-PU.1 were
immunoprecipitated from Art/:Bcl2:Spictet and
Art/:Bcl2:Pu.1tet, respectively, after treatment
with imatinib and 2 mM doxycycline for 48 h.
Scatterplot shows number of total peptides per
protein identified bymass spectrometry analysis of
co-immunoprecipitation of SPIC (y axis) versus
PU.1 (x axis).
(B) FLAG-HA-tagged SPIC and FLAG-HA-tagged
PU.1 were immunoprecipitated from Art/:Bcl2:
Spictet and Art/:Bcl2:Pu.1tet abl pre-B cells,
respectively, treated as in (A). IP samples were
immunoblotted (IB) for BCLAF1, IRF4, IRF8, and
FLAG. Asterisk indicates non-specific band.
(C) BCLAF1 was immunoprecipitated from
Art/:Bcl2:Spictet (Spictet) and Art/:Bcl2:Pu.1tet
(Pu.1tet) abl pre-B cells treated as in (A). IP samples
were immunoblotted for BCLAF1 and FLAG.
(D) Dot plot and heatmap of fold changes and
signal intensity for BCLAF1 and SPIC peaks (by
anti-HA ChIP as in Figure 3A) identified by ChIP-
seq in Rag1/:Bcl2:Spictet abl pre-B cells treated
with imatinib and 2 mM doxycycline for 48 h. Data
are from common peaks identified in two repli-
cates of each cell line.
(E) ChIP-qPCR of BCLAF1 binding at the Syk
promoter in Rag1/:Bcl2:Spictet abl pre-B cells
treated with imatinib for 48 h in the absence () or
presence (+) of 2 mM doxycycline (Dox) to induce
SPIC expression.
(F) Re-ChIP for BCLAF1 after primary ChIP for
SPIC or PU.1 (using anti-HA antibodies) in
Rag1/:Bcl2:Spictet or Rag1/:Bcl2:Pu.1tet abl
pre-B cells, respectively, treated with imatinib and
2 mM doxycycline for 48 h.
(G) ChIP-qPCR of BCLAF1 binding at the Syk
promoter in Rag1/:Bcl2 and Art/:Bcl2 abl
pre-B cells treated with imatinib for 48 h.
Data in (A–C) are representative of three indepen-
dent experiments. Data in (E–G) are mean and SE
for three independent experiments. **p % 0.01,
***p% 0.001, and ****p% 0.0001.
See also Figure S3 and Table S1.
(C) ChIP-qPCR validation for PU.1 and SPIC binding at each locus shown in (B). Data are mean and SE for three independent experiments. **p% 0.01, ***p%
0.001, and ****p% 0.0001.
(D) Nucleotide overlap between PU.1 and SPIC peaks identified in (A). Peaks were grouped in bins on the basis of percentage of overlap as shown.
(E) Enrichment of PU.1 and SPIC binding across genomic regions on the basis of ChIP-seq data in (A).
See also Figure S2.
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Figure 5. SPIC and BCLAF1 Regulate Gene Expression in Pre-B Cells in Response to RAG DSBs
(A) Volcano plot of gene expression changes (fold changeR 2, p% 0.05) betweenRag1/:Bcl2:Spictet abl pre-B cells with andwithout SPIC induction. RNA-seq
was performed on Rag1/:Bcl2:Spictet abl pre-B cells treated with imatinib alone ( SPIC) or with imatinib and 2 mMdoxycycline (+ SPIC) for 48 h. Data are from
two independent cultures for each treatment.
(legend continued on next page)
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(Art/:mIgh:Bcl2) (Figures 6A and 6B) (Bednarski et al., 2016).
Loss of BCLAF1 does not alter induction of Spic but does lead
to increased expression of Syk in Art/:mIgh:Bcl2 small pre-B
cells (Figures 6A and 6B). Consistent with the rescue of Syk
mRNA levels, SYK protein is increased in Art/:Igh:Bcl2
pre-B cells lacking BCLAF1 to levels equivalent to those
observed in Rag1/:mIgh:Bcl2 pre-B cells (Figure 6C). On
the basis of these results, we conclude that BCLAF1 is neces-
sary for repression of SYK in response to RAG DSBs in pri-
mary small pre-B cells.
To assess BCLAF1 binding to the Syk promoter during wild-
type pre-B cell development in vivo, we used Spicigfp/igfp mice,
which contain an IRES-EGFP targeted to the 30 non-coding
exon of Spic (Haldar et al., 2014). Approximately 2% of small
pre-B cells from Spicigfp/igfp mice are EGFP positive, indicative
of SPIC expression (Figures 6D and 6E). EGFP-expressing small
pre-B cells are not observed in Atm/:Spicigfp/igfp, indicating
that induction of SPIC (and EGFP) depends on DNA damage
signaling (Figure 6E). SPIC-expressing Spicigfp/igfp small pre-B
cells (EGFP positive) have reduced PU.1 binding and increased
BCLAF1 binding to the Syk promoter as well as decreased Syk
expression (Figures 6F–6H) (Bednarski et al., 2016). These re-
sults suggest that SPIC/BCLAF1 complex is induced by DNA
damage signals from transient RAG DSBs generated during Igl
rearrangement in wild-type small pre-B cells.
Loss of BCLAF1 Alters Large to Small Pre-B Cell
Transition
Activation of SYK downstream of the pre-BCR can promote
pre-B cell proliferation in the absence of IL-7 signaling (Clark
et al., 2014; Herzog et al., 2009; Ochiai et al., 2012; Rolink
et al., 2000; Wossning et al., 2006). Given that loss of BCLAF1
prevents SPIC-mediated repression of SYK, we hypothesized
that lossofBCLAF1mayalter pre-Bcell proliferation and the tran-
sition from large to small pre-B cells during early B cell develop-
ment. To test this, we generated Bclaf1f/f:Mb1-cre mice, which
have selective loss of BCLAF1 in B cells (Figure 7A) (Hobeika
et al., 2006). Pre-B cells from Bclaf1f/f:Mb1-cre and Bclaf1f/f
mice were expanded in the presence of IL-7. Following IL-7 with-
drawal, Bclaf1-deficient pre-B cells from Bclaf1f/f:Mb1-cre mice
have increased S-phase progression and increased Syk expres-
sion compared with pre-B cells from Bclaf1f/f andMb1-cremice
(Figures 7B–7D). These findings support a role for BCLAF1 in the
regulation of pre-B cell proliferation possibly throughmodulation
of SYK activity downstream of pre-BCR signaling.
We next assessed B cell populations in vivo. In our breeding,
Mb1-cre mice have normal numbers of pro-B cells but reduced
pre-B cells relative to littermate wild-type Bclaf1f/f mice (Figures
7E and S6). In contrast, Bclaf1f/f:Mb1-cre mice have increased
numbers of pre-B cells compared with Mb1-cre mice and are
similar to Bclaf1f/f mice (Figure 7E). Interestingly, the increase
in pre-B cells in Bclaf1f/f:Mb1-cre mice is due primarily to larger
numbers of large pre-B cells (Figure 7E). Loss of Bclaf1 does not
alter numbers of pro-B cells or small pre-B cells. Consistent with
findings in cultured cells, in vivo large, proliferating pre-B cells
from Bclaf1f/f:Mb1-cre mice have increased Syk mRNA levels
(Figure 7F).Syk expression is not altered in small pre-B cells (Fig-
ure 7F). We propose that BCLAF1 functions in response to RAG
DSBs in pre-B cells to suppress Syk and enforce transition from
the large to small pre-B cell developmental stage.
DISCUSSION
Here we show that RAG DSBs induce genome-wide changes in
PU.1 localization and function, which coordinates a distinct ge-
netic program in B cells undergoing Ig gene rearrangement.
This modulation of PU.1 activity is mediated by RAGDSB activa-
tion of a SPIC/BCLAF1 transcriptional repressor complex. SPIC
displaces PU.1 at gene regulatory sites but requires association
with BCLAF1 to suppress transcription. This antagonistic
function of SPIC/BCLAF1 coordinates a broad genetic program
and enforces transition from large to small pre-B cells in
response to RAG DSBs.
PU.1 is a key regulator of cell fate decisions during early hema-
topoiesis and is essential for generating B cells from hematopoi-
etic progenitors (Dakic et al., 2007; DeKoter et al., 2002; Pang
et al., 2018; Scott et al., 1994, 1997). PU.1 expression is high
inmyeloid cells, in which it is required to promote lineage specific
gene expression (Heinz et al., 2010). In contrast, PU.1 expres-
sion is reduced during B cell differentiation and remains low in
established B cells (Back et al., 2005; Nutt et al., 2005). This dif-
ferential activity of PU.1 is critical for directing appropriate line-
age commitment. Dysregulation of PU.1 expression leads to
aberrant differentiation and can result in leukemic transformation
(Anderson et al., 2002; Pang et al., 2016; Rosenbauer et al.,
2004, 2006; Sokalski et al., 2011). PU.1 activity is also regulated
through interaction with other transcription factors, which
modulate its DNA binding properties or its transcriptional func-
tion (Maitra and Atchison, 2000; Nerlov et al., 2000; Rogers
et al., 2016). For example, in early lymphoid precursors, E2A
(B)Western blot of BCLAF1 inRag1/:Bcl2:Spictet abl pre-B cells transducedwith a retrovirus expressing a scrambled short hairpin RNA (shRNA) () or shBclaf1
(+) and then treated with imatinib and 2 mM doxycycline for 48 h (to induce SPIC). Data are representative of three independent experiments.
(C) Heatmap of gene expression changes (fold changeR 2, p % 0.05) among Rag1/:Bcl2:Spictet cells without SPIC, Rag1/:Bcl2:Spictet cells expressing
SPIC, andRag1/:Bcl2:Spictet cells expressing SPIC and shBclaf1. Cells were treated as in (A) and (B). Columns represent independent cultures for each cell line
and treatment as indicated. Representative gene are delineated to the right.
(D) ChIP-qPCR of SPIC binding at the Syk promoter inRag1/:Bcl2:Spictet cells expressing a scrambled shRNA () or shBclaf1 (+) and treated as in (B). Data are
mean and SE for three independent experiments. ns, not significant.
(E) Heatmap of gene expression changes (fold changeR 2, p% 0.05) among Rag1/:Bcl2, Art/:Bcl2, and Art/:Bcl2 abl pre-B cells expressing shBclaf1.
Art/:Bcl2 abl pre-B cells were transduced with a retrovirus expressing shBclaf1. RNA sequencing (RNA-seq) was performed on all cells after treatment with
imatinib for 48 h. Columns represent independent cultures for each cell line as indicated. Representative genes are delineated to the right.
(F) Flow diagram showing identification of genes regulated by RAG DSBs, SPIC, and BCLAF1 in pre-B cells.
(G) Representative tracks at genes identified in F from RNA-seq in (C) and (E).
See also Figures S4 and S5 and Tables S2, S3, and S4.
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Figure 6. BCLAF1 Regulates SYK Expression in Primary Pre-B Cells
(A–C) Art/:mIgh:Bcl2 pre-B cells were transduced with a retrovirus expressing a scrambled shRNA () or shBclaf1 (+) and then subsequently withdrawn
from IL-7.
(A and B) Spic and Syk mRNA expression assessed in indicated small pre-B cells 2 days after IL-7 withdrawal. Data are mean and SE for three independent
experiments.
(C) Western blot of SYK and BCLAF1 in indicated small pre-B cells 2 days after IL-7 withdrawal. Data are representative of three independent experiments.
(D) Flow cytometric analysis showing EGFP (y axis) and FSC (x axis) in bonemarrow pre-B cells (B220loCD43IgM) fromwild-type andSpicigfp/igfpmice. Data are
representative of five independent experiments.
(E) Percentage of EGFP-positive small pre-B cells in Spicigfp/igfp (circles) and Atm/:Spicigfp/igfp (squares) mice was quantified by flow cytometry as in (D). Data
are mean and SE from three independent mice of each genotype.
(F–H) Syk mRNA expression (F), ChIP-PCR of PU.1 at Syk promoter (G), and ChIP-PCR of BCLAF1 at Syk promoter (H) in EGFP-negative () and EGFP-ex-
pressing (+) small pre-B cells sorted from Spicigfp/igfp mice. Data in (F) are the mean and SE from three independent experiments. Data in (G) and (H) are
representative of two independent experiments.
*p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001; ns, not significant.
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association with PU.1 inhibits PU.1-induced transcription of
myeloid genes and promotes B lymphoid differentiation (Rogers
et al., 2016). We find that PU.1 activity is regulated at the pre-B
cell developmental stage through RAG DSB-mediated induction
of SPIC, which binds chromatin and displaces PU.1. This tran-
scription factor exchange results in changes in expression of
genes involved in pre-BCR signaling, B cell proliferation, and B
cell differentiation.
SPIC and PU.1 have homologous DNA binding domains
(Bemark et al., 1999; Hashimoto et al., 1999). As such, SPIC
can compete for DNA binding sites occupied by PU.1, and
binding of SPIC results in displacement of PU.1 from these
sites. Interestingly, SPIC associates with >90% of the PU.1
sites, but PU.1 binding is lost at only approximately 20% of
the regions it binds in the absence of SPIC expression (Figures
2D and 3A). It is conceivable, then, that SPIC and PU.1 may
simultaneously bind specific regions of the genome, and
SPIC binding may not always fully displace PU.1. Rather, bind-
ing of SPIC nearby PU.1 may alter PU.1 transcriptional activity
or other transcriptional machinery at these sites. Alternatively,
in an individual cell, each ETS site may be occupied by either
SPIC or PU.1, but ChIP analysis on a bulk population is not
Figure 7. BCLAF1 Regulates Large to Small Pre-B Cell Transition
(A) Western blot of BCLAF1 in sorted CD19 (non-B cell) and CD19+ B cell populations from bone marrow of 5-week-old Bclaf1f/f:Mb1-cre mice. Data are
representative of three independent mice.
(B) Flow cytometric analysis of BrdU incorporation (y axis) and DNA content (7AAD, x axis) performed 24 h after IL-7 withdrawal. Percentage of cells that entered S
phase during BrdU labeling (box) is indicated. Data are representative of at least three independent experiments.
(C) Percentage of cells that entered S phase in cell cycle analysis performed in (B). Data are mean and SE for four independent experiments.
(D) Syk mRNA expression 24 h after IL-7 withdrawal. Data are mean and SE for three independent experiments.
(E) Quantitation of flow cytometric analysis of pro-B cells (B220loIgMCD43+) and pre-B cells (B220loIgMCD43) in bone marrow of 5-week-old Bclaf1f/f (black
bars, n = 12),Mb1-cre (gray bars, n = 9), and Bclaf1f/f:Mb1-cre (white bars, n = 12) mice. Large and small pre-B cells were gated on the basis of forward-scatter
and side-scatter characteristics.
(F)SykmRNA expression in small and large pre-B cells sorted from 5-week-oldBclaf1f/f (black bars, n = 4),Mb1-cre (gray bars, n = 5), andBclaf1f/f:Mb1-cre (white
bars, n = 5) mice.
Data in (E) and (F) are mean and SE for indicated numbers of mice. *p% 0.05, **p% 0.01, and ***p% 0.001; ns, not significant.
See also Figure S6.
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sensitive enough to discriminate between these two different
states.
In early B cells, PU.1 and SPIB are constitutively expressed
and have complementary functions (Schweitzer and DeKoter,
2004; Scott et al., 1994, 1997; Sokalski et al., 2011; Solomon
et al., 2015). As such, conditional deletion of either PU.1 or
SPIB alone mildly alters B cell development, but loss of both
transcription factors results in a block in B cell differentiation
at the pro-B cell stage (Polli et al., 2005; Sokalski et al., 2011;
Su et al., 1997; Ye et al., 2005). PU.1 and SPIB bind to similar
regions throughout the genome of pro-B cells and regulate
expression of key developmental genes, including Syk and
Blnk, which are necessary for pre-BCR signaling and induction
of proliferation of large pre-B cells (Solomon et al., 2015). We
find that SPIC also binds to the same genomic sites as PU.1.
Given that SPIB and PU.1 bind identical regions and have com-
plementary functions in early B cells, SPIC is also expected to
counter SPIB similar to our observed results for PU.1. In
contrast to PU.1 and SPIB, SPIC is inducibly expressed in
pre-B cells in response to RAG DSBs and functions primarily
as a transcriptional repressor. Expression of SPIC opposes
PU.1 and SPIB activity resulting in suppression of pre-BCR
and BCR signaling in early B cells and mature B cells, respec-
tively, leading to a block in B cell maturation or function (Bed-
narski et al., 2016; Zhu et al., 2008). Importantly, complete or
permanent inhibition of PU.1 and SPIB could be detrimental to
B cell development, as combined loss of these transcription
factors results in leukemic transformation (Sokalski et al.,
2011). In this regard, induced expression of SPIC by RAG
DSBs permits for stage-specific and transient inhibition of
PU.1 (and SPIB). SPIC expression is expected to be lost after
RAG DSBs are repaired and associated DDR signaling is termi-
nated. The reduction in SPIC would allow PU.1 (and SPIB) to re-
bind to chromatin and resume transcriptional activities neces-
sary for mature B cell function. Thus, RAG DSBs regulate a tem-
porary suppression of PU.1 to promote transition from large to
small pre-B cells and then permit continued transition to anti-
body-producing mature B cells.
PU.1 forms heterodimeric complexes with IRF4 or IRF8 to pro-
mote transcription (Brass et al., 1996; Heinz et al., 2010; Pongu-
bala et al., 1992). As such, combined loss of IRF4 and IRF8
results in similar abnormalities in B cell development as loss of
PU.1 (Lu et al., 2003; Ma et al., 2006). SPIC binds the same
DNA sequence as PU.1 but has a distinct protein-interaction
domain and does not bind IRF4 or IRF8 (Carlsson et al., 2003).
Thus, SPIC could mediate suppression of transcription simply
through displacement of PU.1 and loss of associated transcrip-
tion activation machinery (i.e., IRF4). Displacement of the PU.1/
IRF4 complex alone, though, may be insufficient to repress tran-
scription as this is not expected to result in rapid changes in his-
tone modifications or RNA polymerase activity, which drive gene
expression. Alternatively, in a manner similar to PU.1, SPIC may
effect transcriptional inhibition by recruiting additional proteins
to gene-regulatory elements. In this regard, we find that SPIC,
but not PU.1, binds BCLAF1. BCLAF1 is not necessary for
SPIC binding to chromatin but is required for transcriptional
repression. On the basis of these findings, we propose that
antagonism of PU.1 activity is mediated by a SPIC-BCLAF1
complex that binds to chromatin and suppresses key PU.1-
regulated genes. Further studies are needed to determine the
mechanism by which the SPIC-BCLAF1 complex regulates tran-
scription (i.e., activity on histone epigenetics, RNA polymerase
activity, and locus accessibility).
BCLAF1 was first identified as a transcriptional repressor but
also functions as an activator to promote expression of p53
and cytokines in response to DNA damage (Kasof et al.,
1999; Liu et al., 2007; Shao et al., 2016). BCLAF1 also has
been identified as a component of the RNA splicing complex
(Savage et al., 2014; Vohhodina et al., 2017). We find that in
early B cells, BCLAF1 complexes with SPIC to repress gene
expression in response to RAG-mediated DSBs. BCLAF1 chro-
matin binding nearly completely overlaps with SPIC-bound
genomic regions. SPIC and BCLAF1 could bind DNA indepen-
dently and then cooperatively suppress transcription. In this
regard, in vitro studies have shown that BCLAF1 binds the
interferon-stimulated response element (ISRE) (Qin et al.,
2019). The sequence for binding of the PU.1/IRF4 heterodimer
contains a portion of the ISRE site in series with an ETS motif.
BCLAF1 and SPIC could bind this same sequence, or, alterna-
tively, BCLAF1 may be recruited to gene regulatory regions
through protein-protein interactions with SPIC, which binds
ETS DNA sequences. The domains that govern SPIC and
BCLAF1 protein interactions and DNA binding are currently be-
ing investigated.
We find that loss of BCLAF1 prevents RAG DSB- and SPIC-
mediated repression of Syk mRNA expression. SYK is a key
signaling molecule downstream of the pre-BCR and is required
for the pre-BCR to promote proliferation of large pre-B cells
(Clark et al., 2014; Herzog et al., 2009). We previously showed
that in response to RAG DSBs, induction of SPIC suppresses
pre-BCR signaling to enforce cell-cycle arrest in small pre-B
cells (Bednarski et al., 2016). Thus, loss of BCLAF1 is expected
to mitigate RAG DSB-induced inhibition of proliferation.
Indeed, Bclaf1-deficient pre-B cells have increased cell cycle
entry, and mice with B cell-specific deletion of BCLAF1 have
increased numbers of proliferating, large pre-B cells, consis-
tent with increased SYK activity. Loss of BCLAF1 does not
result in a complete block in B cell development, which may
reflect that additional mechanisms, such as p53, exist to regu-
late G1 arrest in small pre-B cells undergoing Ig gene
rearrangement.
In summary, we find that SPIC/BCLAF1 functions to modu-
late PU.1 activity in pre-B cells. High activity of PU.1 promotes
proliferation and expansion of large pre-B cells. As cells transi-
tion to small pre-B cell stage and initiate Igl gene assembly,
RAG DSBs induce expression of SPIC, which partners with
BCLAF1, to oppose PU.1 activity resulting in gene expression
changes, including suppression of Syk, that promote transition
from large to small pre-B cells. After rearrangement of Igl is
completed and DSBs are repaired, termination of DDR
signaling would result in cessation of SPIC/BCLAF1 activity
and reestablishment of PU.1 transcriptional activation, which
could support BCR signaling to drive transition to the immature
B cell stage. We propose that RAG DSB-dependent activation
of SPIC/BCLAF1 functions as rheostat to titer PU.1 activity dur-
ing early B cell development.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice: All mice were bred and maintained under specific pathogen-free conditions at the Washington University School of Medicine
and were handled in accordance to the guidelines set forth by the Division of Comparative Medicine of Washington University.Mb1-
cre (Cd79atm1(cre)Reth) micewere purchased from The Jackson Laboratory.Bclaf1f/fmicewere generated by the trans-NIH Knock-Out
Mouse Project (KOMP) and obtained from the KOMP Repository (www.komp.org). Rag1/:mIgh:Bcl2 and Art/:mIgh:Bcl2 were
generated as previously described (Bednarski et al., 2012, 2016). Spicigfp/igfp (Spictm2.1Kmm) were kindly provided by K. M. Murphy
(Haldar et al., 2014). Spicigfp/igfp,Mb1-cre,Bclaf1f/f andBclaf1f/f:Mb1-cremice are on a B6 background. All other mice are on amixed
genetic background. Both sexes were used equivalently in all experiments. In vivo studies were conducted on 4-5 week old mice.
Cell Lines and Primary Cultures
Rag1/:Bcl2 andArt/:Bcl2 abl pre-B cells were a gift fromBarry Sleckman. Cell lines were authenticated by genotyping. To induce
cell cycle arrest and induction of RAG DSBs, cell lines were treated with 3 mM imatinib for indicated times (Bredemeyer et al., 2008).
Primary pre-B cell cultures were generated by culturing bonemarrow from 4-6 week old mice at 23 106 cells/mL in media containing
5 ng/mL of IL-7 (Miltenyi Biotec) for 7-10 days (Bednarski et al., 2012, 2016). Both sexeswere used equivalently in all experiments. For
IL-7 withdrawal experiments, cells were resuspended in media without IL-7 and maintained at 2 3 106 cells/mL for the indicated
times. ATM inhibitor KU55933 (15 mM; Tocris) was added to cultures at time of addition of imatinib or IL-7 withdrawal.
METHOD DETAILS
cDNA Expression and shRNA-Mediated Knock-down
cDNAs for SPIC and PU.1 with 50 FLAG-HA tag were individually cloned into the pFLRU-TRE-Ubc-rtTA-IRES-Thy1.2 lentiviral vector.
shRNA targeting Bclaf1 (sequence: 50-CCTCATAGTCCTTCAC CTATT-30) was cloned into the MSCV-hCD2-mir30 vector (Bednarski
et al., 2012). Retrovirus was produced in platE cells by transfection of the retroviral plasmid with Lipofectamine 2000 (Life Technol-
ogies) according to the manufacturer’s protocol. Lentivirus was produced in 293T cells by transfection of the lentiviral plasmid along
with pCMV-VZV-G and pCMV-d8.2R plasmids with Lipofectamine 2000 (Stewart et al., 2003). Viral supernatant was collected and
pooled from 24-72 hours after transfection. Viral supernatant was used immediately to transduce cells or was concentrated prior to
transduction. To concentrate viral particles, PEG-8000 (Sigma; final concentration 8%) was added to viral supernatant followed by
incubation at 4C overnight and centrifugation at 2500 RPM for 20 minutes. Precipitated virus was resuspended at 300x concentra-
tion in sterile PBS. Pre-B cells were transduced with unconcentrated virus (10 3 106 cells in 1 mL viral supernatant) or with concen-
trated virus (40 3 106 in 1 mL with 10x viral particles) in media with polybrene (5 mg/ml; Sigma) by centrifugation for 90 min at 1300
RPM at room temperature. Four hours later fresh media was added and the cells were incubated overnight. Virus-containing media
was removed and cells were cultured in fresh media (2 3 106/ml). Cells expressing the retrovirus construct were identified by flow
cytometric assessment of hCD25 or hCD2 expression using a FACSCalibur (BD Biosciences). Transduced cells were sorted using
biotin conjugated anti-hCD2 or anti-hCD25 (BD Biosciences) and anti-biotin magnetic beads (Miltenyi Biotec) on MS columns (Mil-
tenyi Biotec) according to the manufacturer’s protocol.
Flow Cytometric Analyses and Cell Sorting
Flow cytometric analyses were performed on a FACSCalibur or BD LSRFortessa (BDBiosciences). Sorting was conducted on a Sony
Sy3200 through the Siteman Cancer Center Flow Cytometry Core Facility. Fluorescein isothiocyanate (FITC)-conjugated anti-
CD45R/B220 (clone RA3-6B2), phycoerythrin (PE)-conjugated anti-CD43 (clone S7), FITC-conjugated anti-CD43 (clone S7), PE-
Cy7-conjugated anti-CD45/B220 (clone RA3-6B2), allophycocyanin (APC)-conjugated anti-IgM (clone II/41), APC-conjugated
anti-hCD2, and PE-conjugated anti-hCD2 were purchased from BD Biosciences. PE-conjugated anti-hCD25 (clone BC96) and
APC-conjugated anti-hCD25 (clone BC96) were purchased from BioLegend.
Cell Cycle Analysis
To assess pre-BCR driven proliferation, pre-B cells were resuspended in media without IL-7 and maintained at 2 3 106 cells/mL.
Twenty-four hours after removal from IL-7 cells were pulsed BrdU for two hours using the BrdU-FITC kit (BD Biosciences) per the
manufacturer’s instructions. DNA content was assessed by 7AAD (BD Biosciences).
Western Blot
Western blots were done on whole cell lysates (Bednarski et al., 2016). Anti-SYK (clone D1I5Q) and anti-GAPDH (clone D16H11) an-
tibodies were from Cell Signaling Technology. Anti-BCLAF1 antibody (A300-608A) was from Bethyl Laboratories. Anti-PU.1 (PA5-
17505) was from Thermo Fisher Scientific. Anti-FLAG (clone M2) was from Sigma. Secondary reagents were horseradish peroxidase
(HRP)-conjugated anti-mouse IgG (Cell Signaling; catalog # 7076) or anti-rabbit IgG (Cell Signaling; catalog # 7074). Westerns were
developed with ECL (Pierce) and ECL Prime (GE Healthcare).
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RT-PCR
For genomic DNA isolation, cells were lysed in lysis buffer (100 mM TRIS pH8.5, 5 mM EDTA, 200mMNaCl and 0.2% SDS) and DNA
was precipitated by addition of isopropanol, washed with 70% ethanol and then resuspended in Tris-EDTA buffer (Bredemeyer et al.,
2008). RNA was isolated using RNeasy (QIAGEN) and reversed transcribed using a polyT primer with SuperScriptII (Life Technolo-
gies) according to the manufacturers’ protocol. RT-PCR was performed using Brilliant II SYBR Green (Agilent) and acquired on an
Mx3000P (Stratagene). Each reaction was run in triplicate. Values were normalized to housekeeping genes as indicated, and fold
change was determined by the DD cycle threshold method. Primer sequences are listed in Table S5.
Chromatin Immunoprecipitation (ChIP) and ChIP-Seq
ChIP was performed using anti-PU.1 (PA5-17505, Thermo Fisher Scientific), anti-FLAG (cloneM2, Sigma), anti-HA (ab9110, Abcam),
anti-BCLAF1 (A300-608A, Bethyl Laboratories), control rabbit IgG (Millipore) and control mouse IgG antibodies (clone P3.6.2.8.1,
eBioscience) as previously described (Bednarski et al., 2016). Briefly, DNA was cross-linked with 2% formaldehyde for 10 min at
room temp (1 3 106 cells/ml). Reaction was stopped with 125 mM Glycine. Cells were lysed with NP-40 and nuclei were frozen in
liquid nitrogen then lysed with SDS. DNA was fragmented by sonicating with 30 s pulses for 60 cycles using a Bioruptor (Diagenode).
DNA fragmentation was in the range of 200-500 bp and was monitored by agarose gel electrophoresis. Immunoprecipitation was
performed with anti-PU.1 (1:100), anti-HA (1 mg), anti-BCLAF1 (2 mg), or control rabbit IgG and Protein A Dynabeads (Life Technol-
ogies). DNA was eluted, reverse cross-linked and then purified with QIAquick PCR purification kit (QIAGEN). For ChIP-PCR analysis,
PCR was performed using Brilliant II SYBR Green (Agilent) and acquired on an Mx3000P (Stratagene). Primers are listed in Table S5.
For ChIP-seq analysis, fragmented DNA was quantified using 2100 Bioanalyzer (Agilent Technologies) and DNA libraries were pre-
pared using Illumina TruSeq. Sequencing was performed using an Illumina HiSeq 3000 by the Washington University Genome Tech-
nology Access Center. Input controls were used for all samples. FASTQ files were aligned to mm9 using Map with Bowtie for Illumina
v. 1.1.2 to the reference genome (NCBI37/mm9) (Langmead and Salzberg, 2012). MACS version 2 was used to call peaks with a tag
size set to 45, bandwidth of 300 and a p value of 13 105 (Zhang et al., 2008). Input. bed files of total reads for MM-ChIP were gener-
ated using Convert from BAM to BED tool v0.1.0 in Galaxy V18.09 (Afgan et al., 2016). Promoter regions were defined as regions
extending 12 kb upstream of transcription start site. R package (GenomicRanges) and Bedtools V2.25.0 were used to determine
overlapping ChIP peaks (Lawrence et al., 2013; Quinlan and Hall, 2010). MAnorm using parameters –w 300–s1 50–s2 50 was
used to calculate normalized fold changes for each ChIP-seq comparison (Shao et al., 2012). A 1.5 fold change magnitude was
used to separate enriched and unbiased peaks for each comparison. EaSeq v1.111 was used to generate ratiometric heatmaps
from RPM-normalized ChIP-seq signal (Lerdrup et al., 2016). Data will be deposited in NCBI’s Gene Expression Omnibus.
Ultra-Low-Input Native ChIP
EGFP-negative (-) and EGFP-expressing (+) small pre-B cells were sorted from SPICigfp/igfp mice. ULI-NChIP was performed as pre-
viously described (Brind’Amour et al., 2015). Briefly, chromatin was fragmented using micrococcal nuclease (New England Biolabs)
at 37C for 5 mins and diluted in complete immunoprecipitation buffer (20mM Tris-HCl pH 8.0, 2mM EDTA,15mM NaCl, 0.1% Triton
X-100, protease and phosphatase inhibitors). Fragmented chromatin was precleared with Protein A Dynabeads (Life Technologies).
Immunoprecipitation was performed with anti-PU.1 (1:100), anti-BCLAF1 (10 mg), or control rabbit IgG and Protein A Dynabeads (Life
Technologies). The antibody-beads complex was washed with low salt (20mM Tris-HCl, pH 8.0, 0.1%SDS, 1% Triton X-100, 0.1%
deoxycholate, 2mMEDTA and 150mMNaCl) and high salt (20mMTris-HCl, pH 8.0, 0.1%SDS, 1% Triton X-100, 0.1% deoxycholate,
2mM EDTA and 300mM NaCl) buffer. DNA was eluted in high salt buffer. DNA was purified and ChIP-PCR was performed as above.
RNA-Seq Analysis
RNA was extracted using RNeasy Kit (QIAGEN). Libraries were prepared using Illumina TrueSeq Adpaters and paired-end
sequencing was performed using an Illumina HiSeq 3000 by theWashington University Genome Technology Access Center accord-
ing to the manufacturer’s protocols. Sequencing data were analyzed as previously described (Andley et al., 2018). Briefly, RNA-seq
reads were aligned to mm9 assembly with STAR version 2.0.4b1. Gene counts were derived from uniquely aligned unambiguous
reads by Subread-featureCount version 1.4.5. Gene-level counts were imported into the R/Bioconductor package EdgeR and
TMM normalization size factors were calculated to adjust for differences in library size (Robinson et al., 2010). Differential expression
analysis was then performed to analyze for differences between conditions using the R/Bioconductor package limma-voom (Law
et al., 2014). Results were filtered for only those genes with Benjamini-Hochberg false-discovery rate adjusted p values less than
or equal to 0.05. DAVID (Database for Annotation, Visualization and Integrated Discovery, v6.8) was used to test if differentially ex-
pressed genes resulted in perturbations in knownGeneOntology (GO) terms and KEGG pathways (Huang et al., 2009). Volcano plots
were generated using R (ggplot2). Java TreeView Version 1.1.6r4 and R/Bioconductor package heatmap3 were used to display heat-
maps (Saldanha, 2004; Zhao et al., 2014). DAVIDwas used to display annotated KEGGgraphs across groups of samples for eachGO
term or KEGG pathway with a Benjamini-Hochberg false-discovery rate adjusted p value% 0.05.
Tandem Affinity Purification and MS Analysis
FLAG-HA-tagged SPIC and PU.1 were immunoprecipitated using anti-FLAG antibody as previously described with the following
modifications (Mosammaparast et al., 2013; Nakatani and Ogryzko, 2003). Cells were lysed lysis of cells (1 3 109 cells/1.5 ml) in
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TAP buffer (50 mM Tris, pH 7.9, 150 mMNaCl, 1%NP-40, and protease and phosphatase inhibitor cocktails (Sigma). The lysate was
cleared by centrifugation and incubated with anti-FLAG beads (40 ml/109 cells; clone M2; Sigma-Aldrich) for 4 hours. After extensive
washing in the same buffer, bound material was eluted with FLAG peptide (Sigma-Aldrich) and analyzed by western blotting. Coo-
massie-stained bands were cut from SDS-PAGE and sent to Taplin Biological Mass Spectrometry Facility at HarvardMedical School
(taplin.med.harvard.edu). In-gel trypsin digestion was performed and the detection of complexed proteins was done using Orbitrap
ion-trap mass spectrometers (ThermoFisher Scientific). Interacting proteins were identified by matching protein database with ac-
quired fragmentation pattern by using Sequest (ThermoFisher Scientific) (Eng et al., 1994).
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-seq and ChIP-seq were analyzed for statistical significance using the software packages described above. For all other ana-
lyses, statistics and figures were generated using Prism 8 (v8.0.2). P values were generated via Student’s t test (unpaired, two-tailed).
Error bars are SE. *p value% 0.05, **p value% 0.01, ***p value% 0.001, ****p value% 0.0001.
DATA AND CODE AVAILABILITY
The ChIP-seq and RNA-seq data generated during this study are available at NCBI Gene Expression Omnibus under accession num-
ber GEO: GSE129130.
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Figure S1. RAG DSBs do not alter PU.1 expression or distribution among genomic regions. Related to Figure 1. (A) 
Western blot of PU.1 levels in Rag1−/−:Bcl2 and Art−/−:Bcl2 abl pre-B cells treated with imatinib for 48 hours. Data are 
representative of three independent experiments. (B) Gene ontology analysis identifying the biological processes related to 
genes neighboring PU.1 ChIP-seq peaks from Figure 1B. (C) Graph depicting enrichment of PU.1 binding across genomic 
regions based on PU.1 ChIP-seq in Figure 1B.
Figure S1
Figure S2. SPIC and PU.1 bind similar genomic regions. Related to Figure 3.  Representative tracks for PU.1 and SPIC 
ChIP-seq at indicated positions from Figure 3B. ChIP-seq was performed as described in Figure 3B.
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Figure S3. Inducible expression of SPIC and PU.1 in pre-B cells. Related to Figure 4. Western blot shows expression 
of FLAG-HA-PU.1 and FLAG-HA-SPIC in Art−/−:Bcl2:Pu.1tet and Art−/−:Bcl2:Spictet, respectively, after treatment with 
imatinib and 2 mM doxycycline for 48 hours (as in Figure 4A). * indicates non-specific band. Data are representative of 
three independent experiments.
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Figure S4. SPIC and BCLAF1 regulate a gene expression in pre-B cells. Related to Figure 5. (A) RT-PCR validation 
of representative gene expression changes from Figure 5C. Data are mean and standard error for three independent 
experiments. **p-value ≤ 0.01, ***p-value ≤ 0.001, ****p-value ≤ 0.0001. (B) Gene ontology analysis depicting immune 
and B cell function pathways related to genes from Figure 5C that are repressed upon SPIC induction in 
Rag1−/−:Bcl2:Spictet cells and rescued following BCLAF1 knockdown. 
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Figure S5. RAG DSBs, SPIC and BCLAF1 regulate a cohort of genes in pre-B cells. Related to Figure 5. (A) 
Heatmap of the 141 genes identified in Figure 5F. Cells were treated as in Figure 5C and 5E. (B) Gene ontology analysis 
depicting immune and B cell function pathways related to the 141 genes identified in the Figure 5F. Representative genes 
in each category are listed. All pathways have p-value ≤ 9.77 x 10-5.
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Figure S6. Analysis of bone marrow B cell populations. Related to Figure 7. Whole bone marrow was stained 
with B220, IgM and CD43 to quantify B cell populations as indicated. Data are representative of three independent 
experiments.
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A2ml1 Frmd4b Ppm1j Ceacam9 Lhfpl4 Sfmbt2
AA467197 Gh Ptafr Cfap70 Lrrc15 Slc15a2
Ackr2 Gm14326 Pygl Clmn Lrrc36 Slc4a5
Acot7 Gnai1 Rab11fip5 Cntd1 Lrrn4 Slc5a11
Aes Gprasp2 Rab44 Col28a1 Lyplal1 Slc5a5
Ahnak2 H2-Aa Rasgrp3 Cpeb1 Mcoln3 Sncb
Angptl4 H2-DMa Rbp2 Crhbp Mfsd2a Sntb1
Ankrd37 Hapln1 Rgs1 Crisp1 Mmp14 Spaca9
Arrdc5 Hck Rgs11 Ctla4 Ms4a1 Stac
Art5 Hhatl Rgs13 Ctnnd2 Myc Steap4
Atf3 Hist1h2ae Rimkla Dll1 Myh7 Taf9b
Bambi Hpn Rpl3 Dmpk Nid2 Tbxas1
BC049352 Hspg2 Rps3a1 Dnajc22 Nkd1 Tcaim
Bcat1 Ifitm3 Rsph1 Dnm1 Nox1 Tdrd9
C4bp Igf2 Rxra Dpt Npr2 Tigit
Cabp1 Il17f Ryr3 Dse Nrxn3 Tmprss4
Cacna1e Il1rn S100a4 Dtx1 Nxph4 Tnfrsf9
Cacna2d1 Il2rb Scd4 Eda2r Olfm1 Tox
Capn11 Iqgap2 Scn11a Etv5 Otog Trp73
Ccnd2 Itih3 Sell Fam129a Paqr4 Tsnaxip1
Ccne1 Kcnn4 Serpina3f Fcer2a Pcdh19 Uaca
Cd86 Kctd14 Serpina3g Fgd4 Pinlyp
Fos Pitpnm3 Wfdc5 Flrt1 Uchl1
Zan Plekhg3 Wnt10b Pipox Vldlr
Table S4. RAG DSBs, SPIC and BCLAF1 cooperatively regulate expression of a cohort of genes in pre-B cells. 
Related to Figure 5. Comparison of RAG DSB-dependent, SPIC-dependent, and BCLAF1-dependent gene expression 
changes from Table S2 and S3.
Primer  Name Application Sequence
Jk1_F qRT PCR for DNA breaks GCTACCCACTGCTCTGTTCC
Jk1_R qRT PCR for DNA breaks CCTTGGAGAGTGCCAGAATC
Syk_F qRT PCR TCTCTGCTGAGCTCCTAGCC
Syk _R qRT PCR CAGAGGCCTCCACAGACTTC
Spic_F qRT PCR TCTCTGCTGAGCTCCTAGCC
Spic_R qRT PCR CAGAGGCCTCCACAGACTTC
B-Actin_F qRT PCR AAACATTTCAAGACGCCATTGAC
B-Actin_R qRT PCR CTCTGACGTGAGGATAAGGGT
Xcrr3_F qRT PCR ATCCTTACGTGGCCTCCTTT
Xcrr3_R qRT PCR TTGTCTGAGAGCTGCCTTGA
Zap70_F qRT PCR TGGTACCTTTTGGCGGTGAAATG 
Zap70 _R qRT PCR ATCTCCGGATCCTTCTGCAAT
Cd86_F qRT PCR GGGGTCTTCGACTGCCTGCG 
Cd86_R qRT PCR GCCTGGCTGATGATGGCCTGC 
Syk _CHIP_F ChIP qRT PCR GGGGAACTGAGCCCTAAAAG
Syk_CHIP _R ChIP qRT PCR TATAGGGGCATGGGTGAGAG
Dapk1_CHIP _F ChIP qRT PCR TCATAGCTACCGTCACACTG
Dapk1_CHIP _R ChIP qRT PCR AACAGATGTGCCTAAGGTTC
Cd200_CHIP_F ChIP qRT PCR GCTAGGATCAAAAGAATCCAGTC
Cd200_CHIP_R ChIP qRT PCR GCTAGGATCAAAAGAATCCAGTC
Sos2_CHIP_F ChIP qRT PCR TGAAGTTAGAGGGCCTGTCTG
Sos2_CHIP_R ChIP qRT PCR AGGAAAGGAGGCAGCTTGAC
Rag1_1 Genotyping AGAAGGAGAAGGATTCCTCAGAGGGG
Rag1_2 Genotyping TTGGGAAGTAGACCTGACTGTGGG 
Rag1_3 Genotyping ACCGCTATCAGGAACATAGCGT
IgH _F Genotyping CAGGGTTATTGTCTCATGAGCGG
IgH _R Genotyping CATTCCTACCTCCACTCTGTCCCT
Bcl2 _F Genotyping CGAGATGTCCAGCCAGCTGCACCTG
Bcl2 _R Genotyping TCACTTGTGGCCCAGATAGGCACCCA
Art_1 Genotyping CAAGAGGCATTCGTGTATATGGGTGGC 
Art_2 Genotyping CCCGTAACAGAGCTATGACAGGACCGGG 
Art_3 Genotyping ACCCCAGGCATATCTGTCACCCC
Mb1 Cre _F Genotyping CATTTTCGAGGGAGCTTCA
Mb1 Cre _R Genotyping ACTGAGGCAGGAGGATTGG
Bcalf1_1 Genotyping AGACTTGGTAACACATACCTGTAATCCC
Bcalf1_2 Genotyping ACTAACACATCCAAATTTTAAGAGCTCC
Bcalf1_3 Genotyping AGCAGAAACTATACTGCCAAGAGTTGC
FlpE_F Genotyping ACTCCGTTAGGCCCTTCATT
FlpE_R Genotyping GCGCCTTATTCAATCTTTGC
Table S5. Primer sequences. Related to STAR methods. List of primers used for genotyping, RT-PCR and 
ChIP-PCR.
